Rare flowers atop the patent cliff: Sanofi picks itself up
This article was originally published in Scrip
Executive Summary
Nobody expected 2012 to be a great year for Sanofi: the global number two pharma company has had to grapple with the loss of market exclusivity in key markets for major brands including the blood thinners Lovenox (enoxaparin) and Plavix (clopidogrel), the antihypertensive Aprovel (irbesartan), the chemotherapeutic Taxotere (docetaxel) and most recently Eloxatin (oxaliplatin). However, the advent of generic competition to Eloxatin in the US in August marked the end of Sanofi's patent cliff for now. And it looks likely that actually, 2012 won't be quite as bad as was once feared.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.